Shawnte Mitchell Sells 15,000 Shares of Olema Pharmaceuticals (NASDAQ:OLMA) Stock

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) insider Shawnte Mitchell sold 15,000 shares of the stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $23.01, for a total value of $345,150.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Shawnte Mitchell also recently made the following trade(s):

• On Wednesday, March 4th, Shawnte Mitchell sold 25,000 shares of Olema Pharmaceuticals stock. The shares were sold at an average price of $24.25, for a total transaction of $606,250.00.

Olema Pharmaceuticals Price Performance

Shares of Olema Pharmaceuticals stock opened at $21.55 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.03 and a quick ratio of 8.03. Olema Pharmaceuticals, Inc. has a fifty-two week low of $2.86 and a fifty-two week high of $36.26. The firm has a fifty day moving average price of $25.16 and a two-hundred day moving average price of $18.06. The company has a market cap of $1.48 billion, a PE ratio of -11.52 and a beta of 1.92.

Institutional Trading of Olema Pharmaceuticals

Several hedge funds have recently modified their holdings of OLMA. Ameritas Investment Partners Inc. boosted its holdings in shares of Olema Pharmaceuticals by 55.4% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,080 shares of the company’s stock worth $26,000 after acquiring an additional 2,168 shares in the last quarter. EverSource Wealth Advisors LLC raised its position in Olema Pharmaceuticals by 9,476.9% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,245 shares of the company’s stock valued at $31,000 after purchasing an additional 1,232 shares during the last quarter. Torren Management LLC acquired a new position in Olema Pharmaceuticals in the fourth quarter worth $44,000. Russell Investments Group Ltd. bought a new stake in shares of Olema Pharmaceuticals during the third quarter worth $53,000. Finally, American Century Companies Inc. bought a new stake in shares of Olema Pharmaceuticals during the second quarter worth $54,000. Institutional investors and hedge funds own 91.78% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on OLMA. HC Wainwright lifted their target price on Olema Pharmaceuticals from $36.00 to $45.00 and gave the stock a “buy” rating in a research report on Thursday, December 11th. Piper Sandler initiated coverage on Olema Pharmaceuticals in a research report on Wednesday, January 7th. They issued an “overweight” rating and a $40.00 price objective for the company. UBS Group started coverage on Olema Pharmaceuticals in a report on Wednesday, January 7th. They set a “buy” rating and a $45.00 price objective on the stock. Stifel Nicolaus initiated coverage on Olema Pharmaceuticals in a research report on Wednesday, February 11th. They set a “buy” rating and a $48.00 price objective on the stock. Finally, Oppenheimer upped their target price on Olema Pharmaceuticals from $45.00 to $48.00 and gave the company an “outperform” rating in a research note on Thursday, December 11th. Nine analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $41.78.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.